natgillin/translations-raw huggingface dataset:
In the case of accidental self-injection, medical advice should be sought immediately and the package leaflet or the label shown to the doctor.
V primeru nenamernega samoinjiciranja takoj poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.
A field study determined the effectiveness of the vaccine in cattle that came from farms where Coxiella burnetii was present.
V terenski študiji so ugotavljali učinkovitost cepiva pri govedu, ki je prihajalo iz kmetij, na katerih je bila prisotna bakterija Coxiella burnetii.
In goats it is very common to see a palpable reaction of 3 to 4 cm diameter at the injection site which may last for 6 days.
Pri kozah se zelo pogosto pojavi otipljiva reakcija tkiva premera 3 do 4 cm na mestu vboda, ki lahko traja šest dni.
The studies conducted in cattle and goats showed that Coxevac reduces bacteria shedding (which is a major factor in spreading the disease) in vaginal discharge and milk, whilst in goats Coxevac reduced bacteria shedding in faeces and the placenta as well.
Študije pri govedu in kozah so pokazale, da cepivo Coxevac zmanjšuje prenos bakterij (ki je glavni dejavnik širjenja bolezni) v nožnično sluz in mleko, medtem ko je pri kozah zdravilo zmanjšalo tudi prenos bakterij v iztrebke in posteljico.
This is of particular importance because Coxiella burnetii can lead to a disease in humans called Qfever and decreasing the disease in animals will decrease the likelihood of transmitting the disease to humans.
To je zlasti pomembno, saj lahko bakterija Coxiella burnetii pri ljudeh povzroči bolezen, imenovano mrzlica Q, z zmanjšanjem okužbe pri živalih pa se bo zmanjšala tudi verjetnost, da bi se bolezen prenesla na ljudi.
What is the risk associated with Coxevac?
Kakšna tveganja so povezana z zdravilom Coxevac?
The CVMP concluded that the benefits of Coxevac exceed the risks for the approved indication and recommended that Coxevac be given a marketing authorisation.
CVMP je zaključil, da so koristi zdravila Coxevac večje od z njim povezanih tveganj, kadar se uporablja za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
Inactivated Coxiella burnetii vaccine
Coxevac cepivo z inaktivirano bakterijo Coxiella burnetii
Coxevac is a veterinary vaccine that contains inactivated (killed) Coxiella burnetii bacteria.
Coxevac je cepivo za uporabo v veterinarski medicini, ki vsebuje inaktivirane (uničene) bakterije Coxiella burnetii.
The studies in goats also showed a lower proportion of abortions in the goats that were vaccinated compared with unvaccinated goats.
Študije pri kozah so pokazale tudi nižji delež splavitev pri cepljenih kozah v primerjavi z necepljenimi.
Coxevac is used in cattle to lower the risk of spreading Coxiella burnetii infection and in goats to reduce abortions caused by the infection as well as reduce spreading the infection.
Zdravilo Coxevac se uporablja pri govedu za zmanjšanje tveganja širjenja okužbe z bakterijo Coxiella burnetii ter pri kozah za zmanjšanje splavitev zaradi okužbe in zmanjšanje širjenja bolezni.
Why has Coxevac been approved?
Zakaj je bilo zdravilo Coxevac odobreno?
Coxevac is available as a suspension for injection.
Na voljo je v obliki suspenzije za injiciranje.
For goats, one injection should be given one year later.
Koze en odmerek cepiva ponovno prejmejo po enem letu.
When Coxevac is given to cattle and goats, their immune system recognises the bacteria contained in the vaccine as ‘foreign' and makes antibodies to defend against them.
Ko govedo ali koza prejme zdravilo Codevax, imunski sistem prepozna bakterijo v cepivu kot „tujek“ in proti njej razvije protitelesa.
In the future, if the animals are exposed to Coxiella burnetii bacteria, the immune system will be able to respond more quickly.
Ob ponovni izpostavitvi živali bakteriji Coxiella burnetii v prihodnosti se bo imunski sistem tako hitreje odzval, kar bo pripomoglo k obrambi pred boleznijo.
This means that it was not possible to obtain complete information about Coxevac at the time of the initial authorisation.
To pomeni, da ob prvotni izdaji dovoljenja za promet z njim ni bilo mogoče pridobiti vseh podatkov o njem.
The effectiveness of the vaccine in goats has been determined in two field studies with pregnant goats exposed to Coxiella burnettii.
Učinkovitost cepiva pri kozah so ugotavljali v dveh terenskih študijah z brejimi kozami, izpostavljenimi bakteriji Coxiella burnetii.
What is Coxevac used for?
Za kaj se zdravilo Coxevac uporablja?
How has Coxevac been studied?
Kako je bilo zdravilo Coxevac raziskano?
What is Coxevac?
Kaj je zdravilo Coxevac?
How does Coxevac work?
Kako zdravilo Coxevac deluje?
In cattle and goats Q-fever can cause abortions, still births and pneumonia.
Povzroča bolezen, ki je znana kot mrzlica Q. Ta lahko pri govedu in kozah povzroči spontani splav, mrtvorojenost in pljučnico.
448 (4 x 112) capsules
448 (4 x 112) kapsul
Capsule, hard bottle (HDPE)
50 mg kapsula, trda peroralna uporaba plastenka (HDPE)
1 Regulation (EC) No 1394/2007
1 Uredba (ES) št. 1394/2007
Some of the concerns were linked to the manufacturing process.
Nekateri pomisleki so bili povezani s proizvodnim postopkom.
Patients who have any questions should speak to their doctor.
Bolniki, ki imajo kakršna koli vprašanja, naj se pogovorijo s svojim zdravnikom.
What was the recommendation of the CAT at that time?
Kakšno je bilo takrat priporočilo CAT?
What consequences does this withdrawal have for patients?
Kakšne so posledice umika za bolnike?
On 14 January 2013, Anika Therapeutics S.r.l.
Družba Anika Therapeutics S.r.l.
This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to repair, regenerate or replace tissue.
Gre za vrsto zdravila, ki vsebuje celice ali tkiva, ki so bili spremenjeni tako, da se lahko uporabljajo za obnovitev, regeneracijo ali nadomeščanje tkiva.
Overall, the results from studies in patients did not justify the proposed use of the product and its safety could not be ascertained conclusively from the data that had so far been presented.
Na splošno rezultati študij pri bolnikih ne upravičujejo predlagane uporabe zdravila, poleg tega pa iz podatkov, ki so bili predloženi do tega trenutka, ni bilo mogoče dokončno potrditi njegove varnosti.
There were also questions about the way the main studies were conducted, such as the failure to randomly select patients for each treatment group, which led to uncertainties about how the results should be interpreted.
Pojavila pa so se tudi vprašanja glede načina izvedbe glavnih študij, saj družba na primer ni zagotovila naključnega izbora bolnikov za posamezne skupine, ki so prejemale zdravljenje, zato so se pojavile nejasnosti glede razlage rezultatov.
Hyalograft C autograft has been used in the following EU countries: Austria, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Lithuania, Poland and Romania, before the introduction of the EU
Madžarskem, v Italiji, Litvi, na Poljskem in v Romuniji.
The main measures of effectiveness were based on the evaluation of patients' cartilage and knee function after treatment.
Glavna merila učinkovitosti so temeljila na oceni delovanja hrustanca in kolena pri bolnikih po zdravljenju.
This application was withdrawn after the CAT had assessed the initial documentation provided by the company and had formulated a list of questions.
Vlogo so umaknili po tem, ko je odbor CAT ocenil začetno dokumentacijo, ki jo je predložila družba, in oblikoval seznam vprašanj.
It was for use in adults experiencing symptoms caused by sudden or repetitive trauma to the cartilage.
Uporabljal naj bi se pri odraslih s simptomi, ki jih povzroči nenadna ali ponavljajoča se poškodba hrustanca.
In its letter notifying the Agency of the withdrawal of application, the company stated that the decision to withdraw the application was based on the outcome of the CAT's preliminary assessment.
Družba je v dopisu, s katerim agencijo obvešča o umiku vloge, navedla, da se je za umik vloge odločila na podlagi rezultatov predhodnega ocenjevanja odbora CAT.
Following this withdrawal, Hyalograft C autograft will no longer be available and healthcare professionals will need to consider other treatment options for patients with femoral cartilage defects.
Zaradi umika vloge avtologni presadek Hyalograft C ne bo več na voljo, zato bodo morali zdravstveni delavci preučiti druge možnosti zdravljenja bolnikov z okvarami hrustanca femoralnega kondila.
The evaluation of advanced therapy products involves an assessment by the Committee for Advanced Therapies (CAT) before an opinion is adopted by the Committee for Medicinal Products for Human Use (CHMP).
Postopek ocenjevanja zdravil za napredno zdravljenje mora vključevati oceno Odbora za zdravila za napredno zdravljenje (CAT), preden lahko Odbor za zdravila za uporabo v humani medicini (CHMP) sprejme mnenje.
The company had not yet responded to the CAT's questions at the time of the withdrawal.
Družba v času umika še ni odgovorila na zastavljena vprašanja.
Further data on its benefits and safety were being awaited from the company.
Odbor je čakal, da družba predloži dodatne podatke o koristih in varnosti zdravila.
The main data submitted by the company came from two published studies involving 126 patients with femoral cartilage defects, which compared Hyalograft C autograft with a surgical technique known as microfracture repair.
Glavni podatki, ki jih je predložila družba, so izvirali iz dveh objavljenih študij, ki sta vključevali 126 bolnikov z okvarami hrustanca femoralnega kondila, v katerih so avtologni presadek Hyalograft C primerjali s kirurško tehniko, imenovano postopek mikrofrakture.
At the time of the withdrawal, the CAT had not issued its final recommendation but had some concerns about the data submitted in the application.
Odbor CAT v času umika še ni izdal končnega priporočila, vendar pa je izrazil določene pomisleke glede podatkov, predloženih v podporo vlogi.
The cells are then planted on the square inserts, which are used by a surgeon to fill in the spaces on the bone where cartilage has been damaged.
Celice se nato nasadi na kvadratne vsadke, s katerimi kirurg zapolni prazne prostore na kosti, kjer je bil hrustanec poškodovan.
The company informed the EMA that there were no ongoing clinical trials or compassionate use programmes with Hyalograft C autograft at the time of the withdrawal.
Družba je Evropsko agencijo za zdravila (EMA) obvestila, da v času umika niso potekala nobena klinična preskušanja ali programi sočutne uporabe avtolognega presadka Hyalograft C.
Hyalograft C autograft is a type of advanced therapy product called a ‘tissue engineered product'.
Avtologni presadek Hyalograft C je vrsta zdravila za napredno zdravljenje, ki ga imenujemo „izdelek tkivnega inženiringa“.
officially notified the European Medicines Agency that it wishes to withdraw its application for a marketing authorisation for Hyalograft C autograft, for repairing defects in the cartilage of the femoral condyles and trochlea (the end of the thigh bone that forms part of the knee) caused by sudden or repetitive trauma.
je dne 14. januarja 2013 uradno obvestila Evropsko agencijo za zdravila, da želi umakniti vlogo za pridobitev dovoljenja za promet z avtolognim presadkom Hyalograft C, namenjenim zdravljenju okvar hrustanca femoralnih kondilov in trohlee (končnega dela stegnenice, ki je del kolena), ki jih povzročijo nenadne ali ponavljajoče se poškodbe.
regulation on advanced therapies in 2009.1 Under the regulation, advanced therapies already available in the EU are to undergo an evaluation by the EMA in order to obtain an EU wide marketing authorisation.
1, V skladu z uredbo mora zdravila za napredno zdravljenje, ki so na voljo v EU, oceniti Evropska agencija za zdravila, preden se lahko zanje odobri dovoljenje za promet, veljavno po vsej EU.
Hyalograft C autograft is an implant consisting of cartilage cells derived from the patient and planted on 2x2 cm square inserts.
Avtologni presadek Hyalograft C je vsadek, sestavljen iz hrustančnih celic, ki so bile odvzete bolniku in nasajene na kvadratne vsadke velikosti 2 x 2 cm.
Hyalograft C autograft is made from chondrocytes (cartilage cells) taken from the patient and grown outside the body.
Avtologni presadek Hyalograft C sestoji iz hondrocitov (hrustančnih celic), ki se jih odvzame bolniku in vzgoji zunaj telesa.
Hyalograft C autograft is a ‘combined advanced therapy product' as it incorporates a medical device (the scaffold).
Avtologni presadek Hyalograft C je „kombinirano zdravilo za napredno zdravljenje‟, saj vključuje tudi medicinski pripomoček (nosilec).
What is Hyalograft C autograft?
Kaj je avtologni presadek Hyalograft C?
How does Hyalograft C autograft work?
Kako avtologni presadek Hyalograft C deluje?
Hyalograft C autograft was being evaluated for use in repairing cartilage defects at the end of the femur (the thigh bone), where the bone forms part of the knee joint.
Avtologni presadek Hyalograft C je bil ovrednoten glede uporabe pri zdravljenju okvar hrustanca na končnem delu femorja (stegnenice), tj. delu, ki sestavlja kolenski sklep.
What was Hyalograft C autograft being evaluated for?
Zakaj je bil avtologni presadek Hyalograft C ovrednoten?
B.V. can be started between a few days and 35 days after the attack;
lahko začnejo jemati od nekaj dni po napadu do 35 dni po njem;
It is available as pink, capsule-shaped tablets (75 mg).
Na voljo je v obliki 75-miligramskih rožnatih tablet, ki so podobne kapsulam.
This means that Clopidogrel Teva Pharma B.V. is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
The standard dose of Clopidogrel Teva Pharma B.V. is one 75-mg tablet once a day, taken with or without food.
je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
For genetic reasons, some patients may not be able to convert Clopidogrel Teva Pharma B.V. as effectively as others, which could reduce their response to the medicine.
morda nekateri bolniki zaradi genetskih vzrokov pretvarjajo manj učinkovito kot drugi, zaradi česar je njihov odziv na zdravilo manjši.
This document is a summary of the European public assessment report (EPAR) for Clopidogrel Teva Pharma B.V.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clopidogrel Teva Pharma B.V.
The full EPAR for Clopidogrel Teva Pharma B.V. can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Because Clopidogrel Teva Pharma B.V. is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
generično zdravilo in je biološko enakovredno referenčnemu zdravilu, velja, da so njegove koristi in tveganja enake kot pri referenčnem zdravilu.
Clopidogrel Teva Pharma B.V. can be used in patients who are having a heart attack with ‘ST segment elevation' (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
se lahko uporablja pri bolnikih, ki so imeli srčni napad z „dvigom spojnice ST“ (nenormalni zapis na elektrokardiogramu ali EKG-ju), če zdravnik meni, da jim zdravilo lahko pomaga.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Teva Pharma B.V.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Clopidogrel Teva Pharma B.V., na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z zdravilom in priporočila glede pogojev njegove uporabe.
In acute coronary syndrome, Clopidogrel Teva Pharma B.V. is used together with aspirin and treatment generally starts with a loading dose of four tablets.
uporablja skupaj z aspirinom, zdravljenje pa se na splošno začne z udarnim odmerkom štirih tablet.
For more information about treatment with Clopidogrel Teva Pharma B.V., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Because Clopidogrel Teva Pharma B.V. is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
The active substance in Clopidogrel Teva Pharma B.V., clopidogrel, is an inhibitor of platelet aggregation.
Zdravilna učinkovina v zdravilu Clopidogrel Teva Pharma B.V., klopidogrel, je zaviralec agregacije trombocitov.
• patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
• bolnikom, ki so nedavno utrpeli ishemično kap (kap, ki jo povzroči pomanjkljiva oskrba določenega dela možganov s krvjo); Zdravilo Clopidogrel Teva Pharma B.V.
What are the benefit and risk of Clopidogrel Teva Pharma B.V.?
Kakšne so koristi in tveganja, povezani z zdravilom Clopidogrel Teva Pharma B.V.
Clopidogrel Teva Pharma B.V. is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
se uporablja za preprečevanje aterotrombotičnih dogodkov pri odraslih (težav, ki jih povzročajo krvni strdki v arterijah).
Clopidogrel Teva Pharma
Zdravilo Clopidogrel Teva Pharma
The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel Teva Pharma B.V. to Teva Pharma B.V. on 16 June 2011.
Evropska komisija je dovoljenje za promet z zdravilom Clopidogrel Teva Pharma B.V., veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma B.V.
The CHMP concluded that, in accordance with EU requirements, Clopidogrel Teva Pharma B.V. has been shown to have comparable quality and to be bioequivalent to Plavix.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel Teva Pharma B.V.
The Committee recommended that Clopidogrel Teva Pharma B.V. be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Clopidogrel Teva Pharma B.V.
Clopidogrel Teva Pharma B.V. can be given to the following groups of patients:
se lahko daje naslednjim skupinam bolnikov:
Clopidogrel Teva Pharma B.V. can be started between seven days and six months after the stroke;
lahko začnejo jemati od sedem dni po kapi do šest mesecev po njej;
Other information about Clopidogrel Teva Pharma B.V.:
Druge informacije o zdravilu Clopidogrel Teva Pharma B.V.
• patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
• bolnikom z akutnim koronarnim sindromom, pri katerih se mora zdravilo dajati skupaj z aspirinom
What is Clopidogrel Teva Pharma B.V.?
Kaj je zdravilo Clopidogrel Teva Pharma B.V.
What is Clopidogrel Teva Pharma B.V. used for?
Za kaj se zdravilo Clopidogrel Teva Pharma B.V.
How has Clopidogrel Teva Pharma B.V. been studied?
Kako se zdravilo Clopidogrel Teva Pharma B.V.
How is Clopidogrel Teva Pharma B.V. used?
Kako je bilo zdravilo Clopidogrel Teva Pharma B.V.
Why has Clopidogrel Teva Pharma B.V. been approved?
Zakaj je bilo zdravilo Clopidogrel Teva Pharma B.V.
Invented name Strength Pharmaceutical form
Farmacevtska oblika
Packaging size
Velikost pakiranja
Strength Pharmaceutical Form Route of administration
Številka EU Izmišljeno ime Jakost Farmacevtska oblika
Especially tell your doctor:
Še zlasti morate zdravniku povedati:
Make sure to ask your doctor for advice regarding when you can start your treatment again.
Ne pozabite vprašati vašega zdravnika za nasvet, kdaj lahko ponovno začnete z vašim zdravljenjem.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 16 January, 2014
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM 16. januar 2014
Do not take this medicine if any of the above apply to you.
Ne jemljite tega zdravila, če karkoli od navedenega velja za vas.
These conditions can cause dehydration.
Vse to lahko povzroči dehidracijo.
• For renal function approaching moderate renal impairment, at least 2 to 4 times per year.
• V primeru delovanja ledvic, ki se bliža zmerni okvari ledvic, vsaj 2- do 4-krat na leto.
• Prior to initiation of concomitant medicinal products that may reduce renal function and periodically thereafter
• Pred uvedbo sočasnih zdravil, ki lahko zmanjšajo delovanje ledvic, in redno pozneje.
It particularly effects patients whose kidneys are not working properly.
Pojavi se zlasti pri bolnikih, ki jim ledvice ne delujejo pravilno.
This is a build up of lactic acid in the blood that can cause death.
Gre za kopičenje mlečne kisline v krvi, ki lahko povzroči smrt.
Monitoring of renal function is recommended as follows:
Delovanje ledvic je priporočljivo kontrolirati takole:
Diagnosis
Diagnoza
You will need to tell your doctor and stop taking this medicine for a certain period of time and for 2 or more days after depending on how your kidneys are working.
To boste morali povedati zdravniku in nehati jemati to zdravilo za določeno obdobje v času rentgenske preiskave ter 2 ali več dni po njej, odvisno od delovanja vaših ledvic.
Lactic acidosis is a medical emergency and must be treated in hospital.
Laktacidoza je nujno stanje, ki ga je treba zdraviti v bolnišnici.
• if you are going to have an operation under anaesthesia.
• če imate predvideno operacijo v anesteziji.
More information is given below in ‘Other medicines and Xigduo'.
Več informacij najdete v poglavju "Druga zdravila in zdravilo Xigduo",
15% of the dose was excreted as parent drug.
V blatu se je približno 15 % odmerka izločilo kot matično zdravilo.
Gastrointestinal symptomsi,§
Bolezni prebavil gastrointestinalni simptomii,§
As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia.
To zdravilo vsebuje metformin, zato je zdravljenje treba prekiniti 48 ur pred elektivno operacijo, ki bo opravljena v splošni, spinalni ali epiduralni anesteziji.
Your kidneys should be checked before you start taking this medicine and at least once every year whilst you are taking it.
Delovanje ledvic je treba preveriti pred začetkom jemanja tega zdravila in vsaj enkrat vsako leto med zdravljenjem.
• Prior to initiation of treatment and at least yearly thereafter (see sections 4.2, 4.8, 5.1 and 5.2)
• Pred uvedbo zdravljenja in nato vsaj enkrat na leto (glejte poglavja 4.2, 4.8, 5.1 in 5.2).
• if you have a condition called ‘diabetic ketoacidosis', a problem you can get with diabetes.
• če imate motnjo, ki jo imenujemo "diabetična ketoacidoza"; to je težava, ki se lahko pojavi pri sladkorni bolezni.
If metabolic acidosis is suspected, treatment with the medicinal product should be discontinued and the patient hospitalised immediately (see section 4.9).
Če obstaja sum na metabolično acidozo, je treba zdravljenje s tem zdravilom prekiniti in bolnika takoj hospitalizirati (glejte poglavje 4.9).
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away.
Takoj nehajte jemati to zdravilo in nemudoma obvestite zdravnika ali najbližjo bolnišnico.
(≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti iz razpoložljivih podatkov).
• if you are taking a medicine used to remove water from the body (diuretic).
• če jemljete kakšno zdravilo za odvajanje vode iz telesa (diuretik).